SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated November 09, 2011
(Commission File No. 1-15024)
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F: x |
|
Form 40-F: o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes: o |
|
No: x |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes: o |
|
No: x |
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: o |
|
No: x |
|
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com |
- Investor Relations Release -
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
Basel, November 9, 2011 Novartis announced the appointment of Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals effective immediately.
Dr Wright joined Novartis in 2004 and most recently served as Senior Vice President and Global Head of Translational Sciences at Novartis Institutes for BioMedical Research (NIBR). His group included Translational Medicine, Biomarker Development, Preclinical Safety (toxicology), and Drug Metabolism and Pharmacokinetics. Previously, he worked for Pfizer Global Research and Development as the Exploratory Therapy Area Leader for Inflammation. He also served as Chief of the Division of Rheumatology and Clinical Immunology and an endowed professor at the University of Pittsburgh.
Dr Wright received a B.A. in Biology from the University of Delaware and a medical degree from the Johns Hopkins University School of Medicine.
Disclaimer
The foregoing release contains forward-looking statements including express or implied discussions regarding the potential impact of Dr. Wrights leadership on Novartis pharmaceuticals development. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any particular results will be achieved under Dr. Wrights leadership. In particular, managements expectations could be affected by, among other things, unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Groups continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
e-mail: media.relations@novartis.com
Novartis Investor Relations
Central phone: |
|
+41 61 324 7944 |
|
|
|
|
Susanne Schaffert |
|
+41 61 324 7944 |
|
North America: |
|
|
Pierre-Michel Bringer |
|
+41 61 324 1065 |
|
Richard Jarvis |
|
+1 212 830 2433 |
Thomas Hungerbuehler |
|
+41 61 324 8425 |
|
Jill Pozarek |
|
+1 212 830 2445 |
Isabella Zinck |
|
+41 61 324 7188 |
|
Edwin Valeriano |
|
+1 212 830 2456 |
|
|
|
|
|
|
|
e-mail: investor.relations@novartis.com |
|
e-mail: investor.relations@novartis.com |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Novartis AG | |
|
| |
|
| |
Date: November 09, 2011 |
By: |
/s/ MALCOLM B. CHEETHAM |
|
|
|
|
Name: |
Malcolm B. Cheetham |
|
Title: |
Head Group Financial Reporting and Accounting |